| Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy PE Czabotar, G Lessene, A Strasser, JM Adams Nature reviews Molecular cell biology 15 (1), 49-63, 2014 | 3646 | 2014 |
| The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models A Kotschy, Z Szlavik, J Murray, J Davidson, AL Maragno, ... Nature 538 (7626), 477-482, 2016 | 1099 | 2016 |
| Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production MJ White, K McArthur, D Metcalf, RM Lane, JC Cambier, MJ Herold, ... Cell 159 (7), 1549-1562, 2014 | 921 | 2014 |
| BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis K McArthur, LW Whitehead, JM Heddleston, L Li, BS Padman, V Oorschot, ... Science 359 (6378), eaao6047, 2018 | 851 | 2018 |
| BCL-2 family antagonists for cancer therapy G Lessene, PE Czabotar, PM Colman Nature reviews Drug discovery 7 (12), 989-1000, 2008 | 816 | 2008 |
| Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death JM Hildebrand, MC Tanzer, IS Lucet, SN Young, SK Spall, P Sharma, ... Proceedings of the National Academy of Sciences 111 (42), 15072-15077, 2014 | 610 | 2014 |
| Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2 T Klemm, G Ebert, DJ Calleja, CC Allison, LW Richardson, JP Bernardini, ... The EMBO journal 39 (18), e106275, 2020 | 463 | 2020 |
| Structure-guided design of a selective BCL-XL inhibitor G Lessene, PE Czabotar, BE Sleebs, K Zobel, KN Lowes, JM Adams, ... Nature chemical biology 9 (6), 390-397, 2013 | 454 | 2013 |
| Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity ZF Tao, L Hasvold, L Wang, X Wang, AM Petros, CH Park, ER Boghaert, ... ACS medicinal chemistry letters 5 (10), 1088-1093, 2014 | 335 | 2014 |
| BH3-mimetic drugs: blazing the trail for new cancer medicines D Merino, GL Kelly, G Lessene, AH Wei, AW Roberts, A Strasser Cancer cell 34 (6), 879-891, 2018 | 319 | 2018 |
| MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis AL Samson, Y Zhang, ND Geoghegan, XJ Gavin, KA Davies, ... Nature communications 11 (1), 3151, 2020 | 288 | 2020 |
| The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs ST Diepstraten, MA Anderson, PE Czabotar, G Lessene, A Strasser, ... Nature Reviews Cancer 22 (1), 45-64, 2022 | 262 | 2022 |
| The mitochondrial apoptotic effectors BAX/BAK activate caspase-3 and-7 to trigger NLRP3 inflammasome and caspase-8 driven IL-1β activation JE Vince, D De Nardo, W Gao, AJ Vince, C Hall, K McArthur, D Simpson, ... Cell reports 25 (9), 2339-2353. e4, 2018 | 214 | 2018 |
| Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations RW Birkinshaw, J Gong, CS Luo, D Lio, CA White, MA Anderson, ... Nature communications 10 (1), 2385, 2019 | 212 | 2019 |
| Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer D Merino, JR Whittle, F Vaillant, A Serrano, JN Gong, G Giner, ... Science translational medicine 9 (401), eaam7049, 2017 | 200 | 2017 |
| Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis EJ Petrie, JJ Sandow, AV Jacobsen, BJ Smith, MDW Griffin, IS Lucet, ... Nature communications 9 (1), 2422, 2018 | 195 | 2018 |
| Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia DM Moujalled, G Pomilio, C Ghiurau, A Ivey, J Salmon, S Rijal, S Macraild, ... Leukemia 33 (4), 905-917, 2019 | 180 | 2019 |
| HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death AV Jacobsen, KN Lowes, MC Tanzer, IS Lucet, JM Hildebrand, EJ Petrie, ... Cell death & disease 7 (1), e2051-e2051, 2016 | 170 | 2016 |
| Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1 JN Gong, T Khong, D Segal, Y Yao, CD Riffkin, JM Garnier, SL Khaw, ... Blood, The Journal of the American Society of Hematology 128 (14), 1834-1844, 2016 | 162 | 2016 |
| Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 TC Teh, NY Nguyen, DM Moujalled, D Segal, G Pomilio, S Rijal, ... Leukemia 32 (2), 303-312, 2018 | 159 | 2018 |
Peter CzabotarThe Walter & Eliza Hall Institute of Medical ResearchEmail yang diverifikasi di wehi.edu.au
